Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 351 to 375 of 2047

TitleReference numberPublishedLast updated
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
TuberculosisNG33
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Devices for remote monitoring of Parkinson's diseaseHTG657
COVID-19 rapid guideline: managing the long-term effects of COVID-19NG188
Temperature control to improve neurological outcomes after cardiac arrestHTG710
Pharyngeal electrical stimulation for neurogenic dysphagiaHTG709
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Sebelipase alfa for treating Wolman diseaseHST30
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Intravascular lithotripsy for calcified arteries in peripheral arterial diseaseHTG707
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Middle meningeal artery embolisation for chronic subdural haematomasHTG706
Digitally enabled therapies for adults with anxiety disorders: early value assessmentHTG676
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Velmanase alfa for treating alpha-mannosidosisHST29
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939

Results per page

  1. 10
  2. 25
  3. 50
  4. All